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The human hepatoma line Hep G2 produces an acid- and SDS-sensitive plasminogen activator inhibitor 
(PAI). This protein has been previously purified and used to raise polyclonal antibodies. This antiserum 
has been used to isolate cDNA clones from a human placental gtl 1 cDNA library. The immunologically 
positive clones were screened for expression of recombinant proteins which inhibit urokinase activity and 
form an inhibitor-enzyme complex with izSI-urokinase. Two positives (IPAI 11.1 and lPAI 14.1) have been 
obtained. The cDNA insert of the longer isolate (IPAI 14.1) consists of 1962 base pairs encoding the entire 
mature Hep G2 PAI and a 3’-noncoding region of 801 base pairs. The clone apparently lacks portions 
of S- and 3’-untranslated sequences. The translated amino acid sequence matches the sequence obtained 
for the mature Hep G2 PAI and consists of 379 amino acids with a molecular mass of 42 770 Da. Interesting- 
ly, this PA1 clone is quite different from the placental-type PAI- sequence as expected, but matches the 
sequence of the endothelial-type PAI (PAI- 1) reported to be acid-insensitive and SDS-enhancible. 
Plasminogen activator inhibitor; cDNA sequence; Phage llgt 11; (Hep G2 hepatoma cell) 
1. INTRODUCTION 
The mammalian serine protease, plasminogen 
activator (PA), catalyzes the conversion of the pro- 
tease zymogen plasminogen to the active protease, 
plasmin. This enzyme system plays an important 
role in a variety of biological functions (reviews 
[l-3]). Two distinct types of plasminogen ac- 
tivator have been identified, tissue-type lasmin- 
ogen activator (tPA) and urokinase-type plasmin- 
ogen activator (uPA). 
Both uPA and tPA are regulated by specific 
plasminogen activator inhibitors (PAIs). At least 
three immunologically distinct PAIs are known to 
exist in a variety of cells, tissues and biological 
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fluids. These include protease nexin [4], en- 
dothelial cell-type PA1 (PAI-1) (the term PAI- 
refers to the plasminogen activator inhibitor of en- 
dothelial cells, platelets, and HT1080 cells, while 
PAI- refers to the plasminogen activator inhibitor 
of placenta, monocytes and U-937 cells, in accor- 
dance with the recommendations adopted at the 
32nd annual meeting of the International Commit- 
tee on Thrombosis and Haemostasis, June 8, 1986) 
[5], and placental-type PA1 (PAI-2) [6]. Recently, 
we have isolated two immunologically unrelated 
PAIs from human placenta (Wun, T.-C. and 
Reich, E., submitted) and Hep G2 hepatoma cells 
(Wun, T.-C. and Palmier, M., in preparation). To 
facilitate further biochemical studies, we have 
undertaken molecular cloning of the respective 
genes. The cloning of the the cDNA for PAI- is 
reported elsewhere (Ye, R.D. et al., submitted). 
Here we describe the cloning of the cDNA cor- 
responding to PAI-1. 
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2. EXPERIMENTAL 4°C. The lysate was recovered and bacterial debris 
removed by centrifugation. 
2.1. Materials 
The Xgt 11 placental cDNA library constructed 
by the method of Millan [7] was obtained from 
Clonetech. The protoblot immunoscreening kit 
was purchased from Promega Biotech. Restriction 
enzymes, calf intestine alkaline phosphatase, DNA 
polymerase I (Klenow), exonuclease III, and Sr 
nuclease were purchased from New England 
Biolabs; dNTPs, from P.L. Biochemicals; 
5 ’ -[a-35S]thio-dATP (600 Ci/mmol) and Ml3 se- 
quence kit, from Amersham. The purifications of 
urokinase and plasminogen and iodination of 
urokinase were carried out as in [8]. Purification 
of PA1 from Hep G2 conditioned medium and the 
development of antibody are described elsewhere 
(Wun, T.-C. and Palmier, M., in preparation). 
2.2.3. Screening of urokinase inhibitory activity 
by fibrin-agar spot assay 
9 vols phage lysate was mixed with 1 vol. 
urokinase (5 CTA units/ml, dissolved in PBB) and 
incubated for 30 min at room temperature. 5 ~1 
aliquots were removed and spotted on a fibrin-agar 
plate. The plate was then incubated in a humidified 
chamber at 37°C. Urokinase activity causes the ap- 
pearance of a clear lytic zone and PA1 activity 
causes the abolishmen of the lytic zone. The 
fibrin-agar plate was prepared as in [8]. 
The following buffers were used: PBB - 
phosphate-buffered saline containing 5 mg/ml 
bovine serum albumin and 2.5 mg/ml bovine y- 
globulin; SM buffer - 0.1 M NaCl, 8 mM MgS04, 
50 mM Tris-HCl (pH 7.5), 0.1 mg/ml gelatin; LB 
medium - medium containing 10 g Bacto-tryp- 
tone, 5 g Bacto-yeast extract, and 5 g NaCl per 1. 
2.2.4. SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) analysis of the complex 
formation between lz51-urokinase and 
recombinant proteins expressed by h-phage 
isolates 
Aliquots (0.4 ml) of h-lysate or PBB buffer were 
2.2. Methods 
2.2.1. Screening of Agtll cDNA library 
The Agtl 1 placental cDNA library, consisting of 
lo6 independent recombinant phages, was screened 
immunologically using antiserum against Hep G2 
PA1 as probe. The antiserum was preadsorbed 
with the lysate prepared from BNN97 lysogen to 
reduce the background. Screening was carried out 
using the Protoblot immunoscreening kit (Pro- 
mega Biotech) according to the manufacturer’s 
recommendation. Positive isolates were plaque 
purified and rescreened. 
mixed with 2 ~1 ‘251-urokinase (53 CTA units/ml) 
and incubated at room temperature for 30 min. 
6 ~1 rabbit anti-Hep G2 PA1 serum and 0.1 ml of 
0.1 M benzamidine were added and the mixture in- 
cubated at 4°C overnight. 60 ~1 goat anti-rabbit Ig 
(1 ml precipitates 1.5 mg Ig, Sigma product) was 
then added and the mixture incubated at room 
temperature for 3 h. The mixture was centrifuged 
for 5 min in a microfuge to collect the im- 
munocomplex. The precipitate was washed with 
3 x 1 ml aliquots of a PBS solution supplemented 
with 0.4 M NaCl and 0.1 M benzamidine and then 
with 1 ml PBS. The washed precipitate was then 
dissolved in 30 ~1 of a buffer containing 0.1 M 
glycine/HCl, pH 2.2, 0.1% SDS, 6 M urea, 
20 mM dithiothreitol and 0.001% bromophenol 
blue for SDS-PAGE in a 7.5% polyacrylamide gel 
[lo]. The gel was stained, destained, and dried for 
autoradiography. 
2.2.2. Preparation of h-phage lysates containing 2.2.5. Nucleic acid methods and DNA sequence 
recombinant proteins analysis 
Each plaque-purified hgtll was plated with E. 
coli Y1090 in 8 ml LB-10 mM isopropylthiogalac- 
toside (IPTG)-0.7% agar onto 15-cm LB-agar 
plates at a density of 50000 pfu/plate [9]. The 
plates were incubated at 42°C for 3 h and then at 
37°C for 5 h. 10 ml SM buffer was added to each 
plate and the plates gently shaken overnight at 
Phage suspensions were prepared using a plate 
lysate method [9]. DNA from hgt 11 clones were 
digested with EcoRI endonuclease. The cDNA in- 
sert was subcloned into the pUC19 plasmid [l 11. 
Plasmid DNA was isolated by the method of Birn- 
boim and Doly [12]. The plasmid was digested with 
EcoRI and the cDNA insert isolated by electroelu- 
12 
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tion. The insert was then subcloned in both direc- 
tions into the EcoRI site of Ml3 mp18 [ll]. 
Deletions were generated using exonuclease III 
[ 131. Nucleotide sequence was determined by the 
dideoxy method [14] using [35S]dATPaS and the 
Ml3 sequence kit from Amersham. 
2.2.6. Amino acid sequence analysis 
Purified Hep G2 PA1 was subjected to amino 
acid sequencing on an Applied Biosystems gas- 
phase sequenator. The inhibitor was also digested 
with trypsin and the tryptic peptides separated us- 
ing a C-8 reverse-phase column (Browlee) on an 
Applied Biosystems model 13A separation system. 
Two tryptic peptides were randomly selected for 
sequence analysis. 
3. RESULTS 
3.1. Screening of cDNA library and 
characterization of recombinant proteins 
The placenta cDNA library in Agtl 1 was 
screened using rabbit antiserum against Hep G2 
PAI. Initially, lo6 pfu were screened yielding ap- 
prox. 60 immunologically positive clones. Of these 
Fig.1. Urokinase inhibitory activities in hgtl 1 fusion 
proteins. Phage lysates were incubated with urokinase 
and the mixture spotted on a fibrin-agar plate. 
Urokinase activity is indicated by the appearance of a 
clear lytic zone and PA1 activity is shown by the 
abolishment of the lytic zone. h-lysates tested were from 
clones 1.1, 2.1, 3.1, 4.1, 5.1, 7.1, 8.2, 10.1, 11.1, 14.1, 
Fig.2. SDS-PAGE analysis of the complex formation 
between ‘251-urokinase and PAI inhibitors in the phage 
lysates. Phage lysates containing fusion proteins from 6 
positive clones were incubated with “‘1-urokinase, 
immunoprecipitated by anti-Hep G2 PAI antibody, and 
electrophoresed on a 7.5% polyacrylamide gel as 
described in section 2. APAI clones tested were: a, 1.1; 
b,2.1;c,3.1;d,4.1;e,5.1;f,7.1;g,8.2;h,10.1;i,11.1; 
15.2, hgtll without insert, and a PBB control. j, 14.1; k, 15.1; 1, Agtll; m, PBB control. 
positives, 15 were randomly selected for plaque 
purification and secondary screening. Plate lysates 
of these purified clones were tested for inhibitory 
activity against urokinase and the presence of 
recombinant protein capable of complexing with 
‘*‘I-urokinase. As shown in fig.1, 2 out of 11 im- 
munologically positive clones exhibit inhibitory ac- 
tivity against urokinase on the fibrin-agar spot 
assay. Incubation of ‘*‘I-urokinase with the lysates 
from immunologically positive clones followed by 
SDS-PAGE and autoradiography revealed that the 
same two clones @PA1 11.1 and APAI 14.1) 
formed complexes (-200 kDa) which are im- 
munoprecipitable by antibody against Hep G2 
PAI. Since the natural Hep G2 PA1 and urokinase 
heavy chain have molecular masses of 50 and 
33 kDa respectively, the high molecular mass of 
the complex (200 kDa) supports the notion that the 
recombinant inhibitor is being made as a fusion 
protein with &galactosidase. The clones hPA1 11.1 
and APAI 14.1 were digested with EcoRI and the 
cDNA inserts were found to be 1.4 and 1.9 kb, 
respectively. 
3.2. Nucleotide sequence of PAI cDNA and its 
translated protein sequence 
The APAI 14.1 clone was subjected to Ml3 
subcloning and sequencing by the strategy shown 
in fig.3. The entire sequence was determined on 
ktm 
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Fig.3. Partial restriction map and sequencing strategy for APAI 14.1 insert. The scale at the bottom indicates the 
nucleotide position. The thick bar represents the coding region. The thin bar represents the 3’-noncoding region. The 
restriction endonuclease sites were confirmed by digestion. The arrows show the overlapping Ml3 clones used to 
sequence the cDNA. 
both strands by the exonuclease III deletion 
method [13] and was found to consist of 1962 
bases in length. The sequence is shown in fig.4. It 
contains an open reading frame of 1158 
nucleotides, a stop codon, and 3 ’ -noncoding 
region of 801 nucleotides. The proper reading 
frame and the translated amino acid sequence are 
indicated under the nucleotide sequence. These 
were based on the N-terminal amino acid sequence 
of the purified Hep G2 PA1 matching the predicted 
amino acid sequence (underlined) in fig.4. We have 
also subjected the purified Hep G2 PA1 to tryptic 
digestion and separated the tryptic peptides. Two 
tryptic peptides were randomly selected for se- 
quencing and the sequences were found to corre- 
spond to two separate segments of the coding 
regions as underlined in fig.4. These data strongly 
indicate that the hPA1 14.1 clone corresponds to 
the Hep G2 PA1 and that the clone contains the en- 
tire coding region of the mature protein, 379 
amino acids long with a calculated molecular mass 
of 42770 Da excluding carbohydrate. There are 
three potential N-glycosylation sites at amino acid 
positions 209, 265 and 329. The APAI 14.1 clone 
lacks part of the 5 ‘-untranslated region and ATG 
initiation codon. It also lacks an identifiable 
poly(A) tail at the 3 ‘-end and hence probably at 
least a portion of the untranslated 3 ‘-end. 
4. DISCUSSION 
The present data collectively suggest that the 
cDNA clone isolated from a hgt 11 placental cDNA 
14 
library corresponds to the PA1 produced by the 
Hep G2 hepatoma cell. This includes: (i) the 
recombinant protein coded by the cDNA expresses 
inhibitory activity against urokinase; (ii) the 
recombinant protein forms a complex with 
urokinase not dissociable in SDS-PAGE; (iii) the 
expressed protein reacts with the antibody against 
Hep G2 PAI; and (iv) the amino acid sequences of 
the N-terminal segment and two tryptic peptides 
exactly match those deduced from the cDNA se- 
quence. 
Several other groups have also cloned en- 
dothelial type PAL Ny et al. [15] used an antibody 
against bovine aortic endothelial PA1 to screen a 
human placenta Agt 11 cDNA library and obtained 
cDNA clones with two different size classes - 1.9 
and 3.0 kb. The 3.0 kb cDNA has been sequenced 
[ 151. Comparison of the cDNA sequence of Ny et 
al. and our own reveals a total match except that 
our clone is shorter at the 3 ’ -untranslated end and 
that our clone is 9 bases longer at the 5’ -end. By 
Northern hybridization analysis, two distinct 
transcripts of 2.2 and 3.0 kb have been detected 
[15]. Therefore, the 1.9 kb cDNAs may have been 
copied from the shorter mRNA transcript. H. Pan- 
nekoek et al. and D. Ginsburg et al. have cloned 
cDNAs for PAI- from human umbilical vein en- 
dothelial cell (personal communication). The com- 
parison of the endothelial clones with the placental 
clones has not yet been reported. 
As discussed elsewhere (Ye, R.D. et al., submit- 
ted), comparison of the translated protein se- 
quences for PAI- and PAI- to other serine 
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-1 +1 
CTC ,T, GCT GAA GCC TCT GCT GTC CAC CAT CCC CC* KC TAC CTG CCC CAC CTC CCC TCA CAC TTC CCC CTG ACC CTC TTT CAG CK CTG 
v., ph. Cly Cl” Cly S.r A,, ‘,,I HI. HI, pro pro 5.r Tyr “.I Al, Hi, Leu Al. SW Asp Ph. Cly “.I Arg “.l Ph. Cln Cln V.l 
91 CCC CAC CCC iCC MC GAC CCC AK CTG GTT TC TCA CCC TAT CCC GTG CCC TCG GTC TTk KC ATC CTC &C CTG ACA A& CGA GCA CAi 
A,. Gin A,. SW Lys A,p Aq Am “,I V.l ph. S.r Pro Tyr CIy “a, Al. S.r “.I L.u Ail. !A.+, ,_.u Cl” ,..u Thr Thr Cly Cly Clu 
181 KC CAC CAG CAC ATT CM &A CCT ATC CCi TTC AAC ATT CAT CAC *AC C& ATG CCC CCC CCC CTC CCC CAT CTC TAC AAC CAG CTC ATG 
Thr Gin Cln Gin II. Cln AI. AI. M.t Cly Ph. Ly, II. Asp A.p Lyr Cly Met AI. Pro AI. L.u Arg Ho, L.u Tyr I_y, Clu Lau ~.t 
271 CGC CCC, TGG iAC MC CAT CiC ATC AGC ACi ACA CAC GCG ATC TTC CTC CAG CCC CAT CT6 AAC CTG CTC & CCC TTC AiC CCC CAC TTi 
Cly Pro Trp Am Lys A,p Clu II. SW Thr Thr Asp Al. Il. Ph. V.l Cln Arg Asp Leu Lyr I_.” “al Cln GIy Ph. M.t Pro Hlr ph. 
361 TTC KC CTC TTC CCG *CC KG GTC AK CAi CTC GAC TTT TCA WC GTC GAG MA CCC A& 1TC ATC ATC iAT GAC TGC GTG A.*G ACA CAC 
Ph. Arg I_.” Ph. Arp SW Thr V., l.ys Cln V.I Asp Ph. Ser Clu V., Glu kg AI. Arg Ph. II. II. Asn Asp Trp VaI Lys Thr Hi. 
451 ACA AM CCT iTG ATC AGC MC TTC Cl-T CCi AAA CGA CCC iTC CAC CAC CTC *CA CCC CTi: GTC CTC GTC iAT CCC CTC Tic TTC AK CCC 
Thr Ly, Cly M.t II. S.r Asn L.u L.u Gly Lyr Cly AI. V., Asp Cln L.u Thr kg L.u V.1 L.u “.l Am AI. L.u Tyr Ph. Am Cly 
541 CAC TGC AAC ACT CCC TTC CCC CAC TCC A& KC CAC CCC CGC CTC TTC CAC AAA TCA GAC CCC AK ACT iTC TCT GTC CCC ATG ATG CCT 
Cln Trp Ly. Thr Pro Ph. Pro Asp S.r S.r Thr Hi. A-0 kg L.u Ph. Hi. Ly, Ser kp CIy S.r Thr V.l S.r V., Pro k4.t ,,.t AI. 
631 CAC KC MC MC 7-K. MC TAT ACT GAG TTC KC KC CCC CAT CCC CAT TAC TAC CAC ATC CTC GM CTC CCC TAC CAC GCC CAC KC CTC 
Cln Thr b.n ‘y, Ph. Am Tyr Thr Cl” Ph. Thr Thr Pro Asp Gly HI, Tyr Tyr Asp II. L.u Glu L.u pro Tyr HI, Cly A,p Thr Lsu 
721 ICC ATC TTC iTT GCT CCC CiT TAT GM AAi GAG CTC CCT iTC TCT ‘XC CiC ICC AK Ari CTG ACT CCC SAC CTC ATC A& CAC TCG &AA 
S.r M.t Ph. II. AI. AI. pro Tyr Giu Ly. Glu V., Pro L.u S.r 4,. Lsu Thr Asn II. Lsu S.r AI. Cln L.u II. Ser HI, Trp Ly, 
811 CCC AK ATC KC ICC CTG CCC CCC CTC CTh GTT CTG CCC *AC TTC TCC CTC CAC ACT CA* GTC CAC CTC ICC UC CCC CTA CAC AK CTC 
Cl7 Am M.t Thr Arg L.u Pro Aq L.u L.u V.I L.u Pro Lys Ph. S.r L.u Clu Thr Cl” V.1 A.p L.u Arg Ly. Pro ,_.u Clu Asn ,_.u 
901 
991 
1081 
1171 
1261 
CTC AM ATC GAG GTC AK GAO ACT GCC KC CTG GCC TCC TCA TCC AC* GCT CTC ATA CTC TCA CCC CCC ATG CCC CCC GAG GAG ATC ATC 
V.l Ly, Il. Glu V., Am Clu S.r Cly Thr V.l AI, S.r S.r S.r Thr AI. V.1 II. V., S.r AI. Arg l”.t Al. Pro Glu Clu II. I,. 
ATC GAC AGA CCC TTC CTC TTT CTC GTC CC6 CAC MC CCC iCA CGA ACA CiC CT, TTC AT; CCC CM GTG ATC CAA CCC TiA CCC TGC CaA 
U.t Arp A.rg Pro Ph. L.u Ph. V.l Val Arg HII Am Pro Thr Cly Thr Vat Leu ph. M.t Gly CIn Val M.t Cl” Pro End 
AM KC CCT TCA TCT CCC AtA A.AA CTC GAi ATC CAT CCC CAA ICI ACA AK TCC CIA CIA MC AAT TTT ACT CTT MT GAC TCT TTC TGA 
AGC AAG AGA iW CAT TX CCT TTT 0-T AAi ACA TCC TAA iCC ACA TCT CiC TCC AAG ACi TTC CCC TCT tCT TGC ACG A& m AGC TCA 
1351 AAC TCC CT* iTC TCC ICC TiA WC CCT GGG ACA CM Cl-T TCA AK AC* AiT CCC TTA KC TCT CCA MC iAC KC CTC *‘I; CCT CCC CGA 
1441 
1531 
1621 
1711 
1801 
1891 
CCA TCT CCC hCA CCT CC1 TiC KC CCT CTC TCT KC CAC iC0 CCT CTC CiC KC TGC 7-k CCA CTG AGC CCC TTT GCA GCA CCC AAC TIC 
CCG CCT TIC iCC ACC TTT Tb CTG CCT CCi ACA MC TAT +TC TGT TCC AGT CM ATT CCC ATC ACT CTT bTA CTG CCT CiC A‘C CCG GAG 
GAG CCT CCT GAC AGC CCA AiC ‘XC ACT CCi *GA *AC ICC &T TCA TCT CiC ACT CCA CTi TCC CAC TCG CCA CCC CTC CCC MT ACA CCC 
GTC CTG CAC iTC GCA GAG TiA ATC TCC CCC ATC ATC TCC CCC AN TCT CCT GGC CTG CCC ATC TCC CTC iCC AGA AK ACT GTG CAT CGC 
TTA TTT KC iCT CTA CCT CiC TTG TTT AC? CAT TCA ACC AC1 TTT CTG CiT CCT TTT ATT TT, ATA CGA iTA GAG CM GAA AGC TCA CAT 
CCC TCC CCA ‘iCT CTT CAC CiC CCA ATC TCT TCG TCC CGA CCC CTC TAC CT1 AAT ATT TAT CAT ATC CT, CCC 
CGA AT-2 KC &C ATG TTC AiA CAC TTT CAi: GCT GAC TTC KC ACT CTT TtA GAC CM CAi: CCT CTC CAC &TC CCC CAC C&2 CTC CAG AAi 
Cly M.t Thr A.p M.t Ph. Arg Cln Ph. Cln Al. A.p Ph. Thr S.r L.u S.r Asp Cln Glu Pro I_.” Hi, v., A,. C,n A,. I_.” c,n Lo, 
23 
53 
83 
113 
143 
173 
203 
233 
263 
293 
323 
353 
Fig.4. Nucleotide sequence and translated amino acid sequence of the human PAI- cDNA. Nucleotides are numbered 
on the left and amino acids on the right. The underlined sequences have been independently confirmed by amino acid 
sequence analysis of the purified Hep G2 PAI protein and two tryptic peptides. The valine designated as number 1 is 
the amino-terminus based on sequence match with the amino acid sequence obtained for the purified mature protein. 
protease inhibitors clearly shows that they are hepatoma cells [19] in culture has been reported to 
members of the serpin gene family. Despite the be stable to acid treatment. These PAIs are im- 
fact that PAI- and PAI- possess an overlapping munologically related and are reported to exist 
inhibitory profile and are rather specific inhibitors predominantly in a latent form which can be ac- 
of uPA and tPA, PAI- is no more similar to tivated by treatment with SDS and other 
PAI- than it is to any other mammalian serpin. denaturants. By contrast, our isolated Hep G2 PA1 
PAI-I produced by endothelial cells [5,16,171, is essentially fully active without treatment with 
HT1080 fibrosarcoma cells [18] and Hep G2 denaturant and its inhibitory activity is, on the 
15 
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contrary, labile to SDS and acid treatments. 
Whether these discrepancies reflect a difference in 
the handling of the materials, in the differential 
post-translational processing and modification, or 
in alternative splicing of the mRNA is currently 
under investigation. 
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